Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Add To Watchlist

Recent & Breaking News (TSXV:CLAS.H)

Kalytera retains Colwell Capital for investor relations services

Stockhouse Editorial April 10, 2018

Kalytera Retains Colwell Capital to Provide Investor Relations Services

Business Wire April 10, 2018

Cannabinoid Compound Being Developed As Opiate Substitute

Stockhouse Editorial March 22, 2018

Kalytera Announces Next Issuance of Shares under Services Agreement with Salzman Group

GlobeNewswire March 22, 2018

A New CBD Compound to Treat Chronic Pain?

Stockhouse Editorial March 20, 2018

Kalytera Initiates Program to Develop a Novel Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Business Wire March 20, 2018

Kalytera Announces Grant of Stock Options to Chief Scientific Officer and Chief Medical Officer

GlobeNewswire March 14, 2018

Kalytera Announces Further Issuance of Shares under Services Agreement with Salzman Group

GlobeNewswire February 23, 2018

Kalytera pioneers use of cannabidiol to treat bone marrow patients

Peter Kennedy February 6, 2018

Kalytera Announces Grant of Stock Options

GlobeNewswire January 31, 2018

Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel

GlobeNewswire January 26, 2018

Kalytera Announces Settlement of Debt Transaction

GlobeNewswire January 11, 2018

Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction with The Salzman Group of Israel

GlobeNewswire December 22, 2017

Kalytera Therapeutics, Inc. Announces Closing of Brokered Private Placement

GlobeNewswire December 20, 2017

Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

GlobeNewswire December 7, 2017

Kalytera Confirms No Material Change in Operations

GlobeNewswire December 5, 2017

Kalytera Announces Second US Patent for Prevention and Treatment of Graft Versus Host Disease

Business Wire November 27, 2017

Kalytera Announces $5 Million Private Placement of Convertible Debenture Units

GlobeNewswire November 22, 2017

Kalytera Announces Notice of Allowance of US Patent for Treatment of Graft Versus Host Disease

Business Wire November 15, 2017

Kalytera Therapeutics, Inc. Announces Robert Farrell, J.D. as CEO; Additional Board and Management Changes

Business Wire October 10, 2017